Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP)
CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.